-
公开(公告)号:US20230348571A1
公开(公告)日:2023-11-02
申请号:US17917174
申请日:2021-04-06
申请人: VANDERBILT UNIVERSITY , BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , TRUSTEES OF DARTMOUTH COLLEGE
发明人: Ivelin Stefanov Georgiev , Andrea R. Shiakolas , Kevin J. Kramer , James E. Crowe, Jr. , Robert Carnahan , Nianshuang Wang , Daniel Wrapp , Jason McLellan
CPC分类号: C07K16/1003 , A61P31/14 , A61K2039/505
摘要: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
-
公开(公告)号:US12077563B2
公开(公告)日:2024-09-03
申请号:US18411284
申请日:2024-01-12
发明人: Jason McLellan , Ching-Lin Hsieh , Scott Rush , Nianshuang Wang
IPC分类号: C07K14/08 , C07K14/115 , C07K14/135
CPC分类号: C07K14/08
摘要: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.
-
公开(公告)号:US11919927B2
公开(公告)日:2024-03-05
申请号:US18296771
申请日:2023-04-06
发明人: Jason McLellan , Ching-Lin Hsieh , Scott Rush , Nianshuang Wang
IPC分类号: C07K14/08 , C07K14/115 , C07K14/135 , C12N7/00
CPC分类号: C07K14/08
摘要: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.
-
公开(公告)号:US20230113170A1
公开(公告)日:2023-04-13
申请号:US17798021
申请日:2021-02-11
申请人: The United States of America, as represented by the Secretary, Department of Health and Human , Board of Regents, The University of Texas System , Trustees of Dartmouth College
发明人: Barney Graham , Kizzmekia Corbett , Olubukola Abiona , Geoffrey Hutchinson , Jason McLellan , Daniel Wrapp , Nianshuang Wang
IPC分类号: A61K39/215 , C12N15/86 , A61P31/14
摘要: SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
-
-
-